Abstract
We have carried out a prospective study to investigate whether orbital radiotherapy combined with high dose systemic glucocorticoids is more effective than orbital radiotherapy alone for Graves’ ophthalmopathy. Thirty consecutive patients with relevant and active Graves’ ophthalmopathy were randomly assigned to treatment either with orbital radiotherapy combined with systemic glucocorticoids (Group 1, n =15) or with orbital radiotherapy alone (Group 2, n = 15). The final evaluation was made 6–9 months after beginning treatment. Two patients in each group were lost to follow-up. Ocular involvement and response to treatment were evaluated by the ophthalmopathy index and by clinical assessment. Mean ophthalmopathy index values were 5.85 in Group 1 and 5.46 in Group 2 (p = NS) before treatment, and 2.46 in Group 1 and 3.61 in Group 2 after treatment (p = 0.0001 and p = 0.003 vs initial value, respectively). The mean ophthalmopathy index decrease in Group 1 (−3.39) was significantly greater (p = 0.043) than that in Group 2 (−1.85). Favorable responses on clinical ground occurred in 9 patients (69%) in Group 1 and in 5 patients (38%) in Group 2. The difference was particularly evident on soft tissue changes and extraocular muscle involvement. Severe eye muscle restriction was substantially unaffected by either treatment. In conclusion, the association of orbital irradiation and high dose systemic glucocorticoids in the treatment of severe Graves’ ophthalmopathy provides more favorable responses than orbital radiotherapy alone.
Similar content being viewed by others
References
Jacobson D.H., Gorman C.A. Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis and treatment. Endocr. Rev. 5: 200, 1984.
McConahey W.M. Medical therapy. In: Gorman C.A., Waller R.R., Dyer J.A., (Eds.), The eye and orbit in Graves’ disease. Raven Press New York: 1984, p. 317.
Pinchera A., Bartalena L., Chiovato L., Marcocci C. Radiotherapy of Graves’ ophthalmopathy. In: Gorman C.A., Waller R.R., Dyer J.A., (Eds.), The eye and orbit in Graves’ disease. Raven Press New York: 1984, p. 301.
Pinchera A., Bartalena L., Marcocci C., Ceccarelli P., Cucchi P., Vitti P., Mariotti S., Fenzi G.F. Humoral autoimmunity in endocrine ophthalmopathy. Acta Endocrinol. (Copenh) 121(Suppl. 2): 112, 1989.
Kriss J.P. Pathogenesis and treatment of Graves’ ophthalmopathy. Thyroid Today 7: 1, 1984.
Bartalena L., Marcocci C., Chiovato L., Laddaga M., Lepri G., Andreani D., Cavallacci G., Baschieri L., Pinchera A. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J. Clin. Endocrinol. Metab. 56: 1139, 1983.
Kriss J.P., Petersen I.A., Donaldson S.S., McDougall I.R. Supervoltage orbital radiotherapy for progressive Graves’ ophthalmopathy: results of a twenty-year experience. Acta Endocrinol. (Copenh.) 121(Suppl 2): 154, 1989.
Werner S.C. Modification of the classification of the eye changes of Graves’ disease: recommendations of the ad hoc Committee of the American Thyroid Association. J. Clin. Endocrinol. Metab. 44: 203, 1977.
Donaldson S.S., Bagshaw M.A., Kriss J.P. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 37: 276, 1983.
Marcocci C., Bartalena L., Panicucci M., Marconcini C., Cartei F., Cavallacci G., Laddaga M., Campobasso G., Baschieri L., Pinchera A. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves’ ophthalmopathy: a comparative study. Clin. Endocrinol. (Oxf.) 27: 33, 1987.
Mourits M., Koornneef L., Wiersinga W.M., Prummel M.F., Berghout A., van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br. J. Ophthalmol. 73: 639, 1989.
Brown J., Coburn J.W., Wigod R.A., Hiss J.M., Dowling J.T. Adrenal steroid therapy of severe infiltrative ophthalmopathy of Graves’ disease. Am. J. Med. 34: 786, 1963.
Werner S.C. Prednisone in emergency treatment of malignant exophthalmos. Lancet 1: 1004, 1966.
Kahaly G., Schrezenmeir J., Krause U. Ciclosporin and prednisone v. prednisone in the treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur. J. Clin. Invest. 16: 415–22, 1986.
Covington E.E., Lobes L., Sudarsanam A. Radiation therapy of exophthalmos: report of seven cases. Radiology 122: 797, 1976.
Olivotto A., Ludgate C.M., Allen L.H., Rootman J. Supervoltage radiotherapy for Graves’ ophthalmopathy: CCABC technique and results. Int. J. Radiat. Oncol. Biol. Phys. 11: 2085, 1985.
Bartalena L., Marcocci C., Bogazzi F., Panicucci M., Lepri A., Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N. Engl. J. Med. 321: 1349, 1989.
Bartalena L., Marcocci C., Bogazzi F., Bruno-Bossio G., Pinchera A. Glucocorticoid therapy of Graves’ ophthalmopathy. Exp. Clin. Endocrinol. 97: 320, 1991.
Marcocci C., Bartalena L., Bogazzi F., Bruno-Bossio G., Pinchera A. Role of orbital radio therapy in the treatment of Graves’ opthalmopathy. Exp. Clin. Endocrinol. 97: 332, 1991.
Bartalena L., Marcocci C., Bogazzi F. A new ophthalmopathy index for quantitation of eye changes of Graves’ disease. Acta Endocrinol. (Copenh.) 121(Suppl 2): 190, 1989.
Bahn R.S., Garrity J.A., Bartley G.B., Gorman C.A. Diagnostic evaluation of Graves’ ophthalmopathy. Endocrinol. Metab. Clin. North. Am. 17: 527, 1988.
Brennan M.W., Leone C.R., Janaki L. Radiation therapy for Graves’ disease. Am. J. Ophtalmol. 96: 195, 1983.
Utiger R.D. Treatment of Graves’ ophthalmopathy. N. Engl. J. Med. 321: 1403, 1989.
Author information
Authors and Affiliations
Additional information
This work was supported in part by grants from Ministero dell’Universita e della Ricerca Scientifica e Tecnologica (MURST) (60%), Rome, Italy.
Rights and permissions
About this article
Cite this article
Marcocci, C., Bartalena, L., Bogazzi, F. et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 14, 853–860 (1991). https://doi.org/10.1007/BF03347943
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347943